SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)			1 Months Ended		3 Months Ended		9 Months Ended
	May 03, 2021	Nov. 09, 2020	Sep. 16, 2021	Oct. 31, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	May 26, 2021	Dec. 31, 2020	Oct. 31, 2020	Oct. 30, 2020	Nov. 01, 2019	Nov. 10, 2017
Research and development expenses					$ 600,000	$ 700,000	$ 1,900,000	$ 2,300,000
Revenue							300,000.0
Outstanding shares of common stock										20,000,000
Working capital deficit					15,900,000		15,900,000
Accumulated deficits					(90,100,000)		(90,100,000)
Federal deposit insurance corporation insured limit					250,000		250,000
Gain on change of fair value					700,000	$ 0	1,100,000	$ 0
Amount in excess of FDIC limit					1,500,000.0		1,500,000.0				$ 1,500,000.0
Allowance for doubtful accounts					80,000.00		80,000.00				40,000.00
Contract liabilities					$ 600,000		$ 600,000				$ 1,000,000.0
Valuation allowance percentage					100.00%		100.00%
Advertising costs					$ 700,000		$ 2,400,000
Non-controlling Interests					$ 0		0
Payment for legal and broker fees							$ 700,000.0
Ownership interest					65.00%		65.00%
Outstanding contingent consideration liability												$ 3,200,000
Merger agreements description							In connection with Sera Labs Merger, Sera Labs security holders are also entitled to receive up to 5,988,024 shares of the Company’s common stock (the “Clawback Shares”)
Conversion price					$ 1.32		$ 1.32		$ 1.32		$ 1.32		$ 1.32
Cash					$ 700,000.0		$ 700,000.0
Initial Principal Payment	$ 200,000	$ 300,000	$ 200,000
Accrued interest rate					18.00%		18.00%
Borrower [Member]
Accrued interest rate														6.00%
Convertible debt										$ 4,000,000				$ 2,000,000.0
Releaf Qualified Financing				$ 15,000,000
Pre money valuation				$ 14,500,000.0
Maturity date				Oct. 31, 2021
Request for conversion description				In the event of a request for conversion by the Company or at the end of the maturity date, October 31, 2021, the outstanding amount of the Releaf Loan and any unpaid accrued interest shall be converted into shares of Releaf based on a price per share on a post money valuation of $10.9 million. In the event Releaf completes a financing round totaling at least $2 million of debt and/or equity (“Releaf Qualified Financing”), the outstanding amount of the Releaf Loan and any unpaid accrued interest shall automatically convert at a price per share paid by the investors in connection with the Releaf Qualified Financing less a discount of 20% on the subscription price.
February 5, 2020 And February 13, 2020 [Member] | Two Convertible Loans [Member]
Accrued interest rate					6.00%		6.00%
Convertible debt					$ 300,000.0		$ 300,000.0
Releaf Qualified Financing							15,000
Pre money valuation							$ 14,500,000.0
Maturity date							Oct. 31, 2021
Request for conversion description							the Company purchased two convertible loans (the “February 2020 Loans”) with Releaf for a total amount of $0.3 million. Releaf shall accrue interest on the February 2020 Loans at 6% per annum and they shall become due and payable to the Company at the earlier of the conversion date or the maturity date of October 31, 2021. In the event of a request for conversion by the Company or at the end of the maturity date, October 31, 2021, the outstanding amounts of the February 2020 Loans and any unpaid accrued interests shall be converted into shares of Releaf based on a price per share on a post money valuation of $10.9 million. In the event Releaf completes a financing round totaling at least $2.0 million of debt and/or equity (“Releaf February 2020 Qualified Financing”), the outstanding amount of the February 2020 Loans and any unpaid accrued interest shall automatically convert at a price per share paid by the investors in connection with the Releaf February 2020 Qualified Financing, less a discount of 20% on the subscription price
Oak Therapeutics [Member]
Ownership interest					63.00%		63.00%								63.00%